`
`TRAVATAN Z Consumers and Patients Rebate
`
`http://www.travatanz.com/
`
`Go
`
`71 captures
`24 Jun 08 2 Jan 17
`
`MAY
`
`2007
`
`Select Text Size:
`
`Small
`Medium
`Large
`
`Rebate Home
`
`TRAVATAN Z® Solution Rebate Worksheet
`
`TRAVATAN Z® Solution Rebate Form
`
`CompleteProductInformation
`
`Save big on your
`TRAVATAN Z® Solution prescription.
`
`REBATE
`
`Restrictions Apply
`Complete your rebate form
`What would my rebate amount be?
`
`You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1
`800FDA1088.
`
`IMPORTANT SAFETY INFORMATION: TRAVATAN Z® solution is indicated for the reduction of elevated intraocular
`pressure (IOP) in patients with openangle glaucoma or ocular hypertension who are intolerant of other IOPlowering
`medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to
`another IOPlowering medication. TRAVATAN Z® solution is contraindicated in patients with known hypersensitivity to
`Exhibit 1027
`http://web.archive.org/web/20080624220702/http://www.travatanz.com/
`ARGENTUM
`
`1/2
`
`000001
`
`
`
`TRAVATAN Z Consumers and Patients Rebate
`2/24/2017
`travoprost or any other ingredients in this product. Prostaglandin analogues, including travoprost ophthalmic solution,
`MAY
`http://www.travatanz.com/
`Go
`0.004%, have been reported to cause changes to pigmented tissues. The most frequently reported changes have been
`71 captures
`increased pigmentation of the iris and periorbital tissue (eyelid) and increased pigmentation and growth of eyelashes.
`2007
`24 Jun 08 2 Jan 17
`These changes may be permanent. TRAVATAN Z® solution may gradually change eye color, increasing the amount of
`brown pigmentation in the iris by increasing the number of melanosomes (pigment granules) in melanocytes. The long term
`effects on the melanocytes and the consequences of potential injury to the melanocytes and/or deposition of pigment
`granules to other areas of the eye are currently unknown. The most common adverse event observed in studies with
`TRAVATAN® solution and TRAVATAN Z® solution was ocular hyperemia which was reported in 30 to 50 percent of
`patients. Ocular events reported at an incidence of 5 to 10 percent included decreased visual acuity, eye discomfort, foreign
`body sensation, pain and pruritus. The recommended dosage is one drop in the affected eye(s) once daily in the evening.
`Before using TRAVATAN Z® solution, please read the full prescribing information.
`
`Copyright © 2008 Alcon, Inc. a global company based in Hünenberg, Switzerland. The information and materials within
`this section pertain to the U.S. market only. Not all products are approved in every marked and approved labeling and
`instructions may vary by local country. See Privacy Policy and Terms & Conditions for the use of this site.
`
`Other Alcon brands: Systane.com ICAPSVitamins.com OptiFree.com Pataday.com Patanase.com Ciprodex.com
`AcrySofReSTOR.com
`
`http://web.archive.org/web/20080624220702/http://www.travatanz.com/
`
`2/2
`
`000002
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
